This filing establishes the legal framework for future debt issuance but does not trigger any immediate dilution. The massive overhang of $69.3M in unsold shelf capacity relative to a $5M market cap signals extreme potential dilution risk. Monitor for any prospectus supplement or 424B filing that would indicate an actual takedown under this shelf — any debt issuance would likely be convertible or distressed in nature given the company's financial position.
Price Chart
Executive Summary
Artelo Biosciences filed Amendment No. 1 to its S-3 shelf registration statement solely to add a form of indenture (Exhibit 4.3) for potential future debt securities. The filing does not specify any offering size, share count, or pricing. The company has a $5M market cap and carries forward $69.3M of unsold securities from a prior S-3. This is a routine administrative step to enable future debt issuance capacity, not an immediate capital raise.
Key Facts
- Amendment No. 1 to S-3 filed on May 14, 2026, solely to add form of indenture for debt securities
- Carries forward $69,293,654.25 of unsold securities from prior S-3 (File No. 333-273153) with no additional filing fee
- Market cap is approximately $5M, making any future issuance highly dilutive relative to current equity
- SEC registration fee for this filing was only $788.05, confirming no new securities registered
- Company is a clinical-stage biotech with no revenue, classified as smaller reporting company and emerging growth company
Financial Impact
No specific offering size disclosed; $69.3M of unsold securities carried forward from prior shelf, which is ~14x current market cap
Risk Factors
- Potential massive dilution if shelf is utilized for equity-linked debt
- Clinical-stage biotech with no revenue — any debt service would consume limited cash runway
- Prior S-3 unsold balance of $69.3M represents ~14x current market cap
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-3/A Filing (Primary) | 0001640334-26-000867 |
| Document: artl_s3a.htm | 0001640334-26-000867 |
| Document: 0001640334-26-000867-index-headers.html | 0001640334-26-000867 |
| Document: 0001640334-26-000867-index.html | 0001640334-26-000867 |
| Document: 0001640334-26-000867.txt | 0001640334-26-000867 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 9, 2026 17d ago | 8-K | $3.11 | awaiting T+60 | — | $2.28 (+26.80%) |
Sep 16, 2026 5w ago | Press Release | $3.75 | awaiting T+60 | — | $2.28 (−39.29%) |
Aug 13, 2026 10w ago | Press Release | $6.83 | awaiting T+60 | — | $2.28 (−66.67%) |
Jul 16, 2026 14w ago | DEFA14A | $1.14 $0.3622 | ▼ −68.23% | ▼ −71.94% | $2.28 (+99.70%) |
Jul 16, 2026 14w ago | Press Release | $1.14 $0.3622 | ▼ −68.23% | ▼ −71.94% | $2.28 (+99.70%) |
Jul 13, 2026 15w ago | Press Release | $1.05 $0.3844 | ▼ −63.39% | ▼ −67.38% | $2.28 (+116.82%) |
Jul 2, 2026 16w ago | DEFA14A | $1.11 $0.4522 | ▲ +59.26% | ▲ +60.98% | $2.28 (−105.10%) |
May 27, 2026 21w ago | 8-K | $1.46 $0.6920 | ▲ +52.60% | ▲ +54.34% | $2.28 (−55.93%) |
May 18, 2026 23w ago | 424B5 | $1.36 $0.7587 | ▼ −44.21% | ▼ −50.50% | $2.28 (+67.40%) |
May 15, 2026 23w ago | 8-K | $1.46 $0.7330 | ▼ −49.79% | ▼ −54.65% | $2.28 (+55.93%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers